AZD 4017

Drug Profile

AZD 4017

Alternative Names: AZD4017

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; University of Birmingham
  • Class Antihyperglycaemics
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors; 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pseudotumour cerebri
  • Discontinued Glaucoma; Obesity; Ocular hypertension; Type 2 diabetes mellitus

Most Recent Events

  • 18 Apr 2017 University of Oxford and AstraZeneca plan a phase II trial for Cushing's syndrome (In volunteers, Combination therapy) in United Kingdom (NCT03111810)
  • 07 Feb 2014 Biomarkers information updated
  • 31 Jan 2014 University of Birmingham plans a phase II trial for Pseudotumour cerebri in UK (NCT02017444)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top